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Background: Depression in MS patients is frequent but often not treated adequately. An important underlying
factor may be physical limitations that preclude face-to-face contact. Internet-based treatment showed to be
effective for depressive symptoms in general and could thus be a promising tool for treatment in MS.
Methods/design: Here, we present a study protocol to investigate the effectiveness of a 5 week Internet-based
self-help problem solving treatment (PST) for depressive symptoms in MS patients in a randomized controlled trial.
We aim to include 166 MS patients with moderate to severe depressive symptoms who will be randomly assigned
to an Internet-based intervention (with or without supportive text-messages) or waiting list control group. The
primary outcome is the change in depressive symptoms defined by a change in the sum score on the Beck
Depression Inventory (BDI-II). Secondary outcomes will include measures of anxiety, fatigue, cognitive functioning,
physical and psychological impact of MS, quality of life, problem solving skills, social support, mastery, satisfaction
and compliance rate. Assessments will take place at baseline (T0), within a week after the intervention (T1), at four
months (T2) and at ten months follow-up (T3: only the intervention group). The control group will be measured at
the same moments in time. Analysis will be based on the intention-to-treat principle.
Discussion: If shown to be effective, Internet-based PST will offer new possibilities to reach and treat MS patients
with depressive symptoms and to improve the quality of care.
Trial Registration: The Dutch Cochrane Center, NTR2772
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Multiple Sclerosis (MS) is a chronic and progressive in-
flammatory autoimmune disorder of the central nervous
system. MS is a relatively common disease -affecting ap-
proximately 1–2 per 1000 individuals- and mainly com-
mences in early to middle adult life. MS patients suffer
from a variety of neurological symptoms such as fatigue,
poor balance, impaired speech, bladder and bowel dys-
function, weakness, pain, spasms, cognitive deficits [1,2].* Correspondence: r.boeschoten@ggzingeest.nl
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distribution, and reproduction in any mediumLifetime risks for depressive disorders in MS patients
are high (~50%) [3]. Findings thus far indicate that de-
pression seems more severe and common in MS com-
pared with healthy people. However, due to overlap of
MS symptomatology with neurovegetative depressive
symptoms such as fatigue, sleeping problems and cogni-
tive impairment, estimated depression prevalence in MS
might be overrated. It also remains unclear to what de-
gree depressive symptoms are a neurological conse-
quence of the disease or a psychological reaction to the
presence of a chronic medical condition with an uncer-
tain and unpredictable course [4]. Some studies that
compared depression in MS with other neurologic con-
ditions and chronic diseases, suggest that depression inntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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logical impact of MS [4-6].
Irrespective of its unclear etiology, depression in MS
patients causes significant suffering and disability. De-
pression is associated with fatigue, cognitive impairment,
and poorer social support [7]. Moreover, it is related to
lower quality of life [8], increased risk of suicide [9] and
may adversely affect health status via effects on the im-
mune system or indirectly by influencing behavior that
affects risk of MS exacerbation [10,11].
However, depression in MS patients often stays un-
diagnosed [12]. There may be several explanations for
the high level of unrecognized depression in MS
patients. It is suggested that MS patients are not actively
screened and diagnosed by their clinician on depression.
In addition, patients could feel resistance to disclose
their emotional problems or perceive them as an unsolv-
able component of the disease, therefore leaving them
unmentioned [3]. Besides, as a result of overlapping
symptomatology, confounded symptoms may be entirely
attributed to MS when in fact a portion of those symp-
toms are attributable to depression. However, depression
does not seem to remit spontaneously and may even
worsen over time if not treated [11].
MS patients seem to respond well to psychothera-
peutic and / or medical treatment for depression [13,14].
Depression in MS patients seems to be related to poor
problem solving skills [7], and learning various coping
strategies has been found to reduce symptoms of depres-
sion in MS patients [14]. Research shows that Cognitive
Behaviour Therapy (CBT) with a focus on developing
sufficient coping skills is preferred to insight-oriented or
supportive group therapy [11,14,15]. Problem Solving
Therapy (PST) is a form of CBT and assumes that de-
pressive symptoms can be caused by (practical) pro-
blems people face in their daily lives combined with
poor problem-solving skills. PST focuses on enabling
people to solve problems by teaching them more ad-
equate problem-solving skills and helping to accept
those problems that cannot be changed [16,17]. PST in
particular seems a favourable treatment for people with
depressive symptoms and a somatic disease [18]. Never-
theless, the literature on PST for depression in MS
patients is limited [19].
Given the evidence for its responsiveness to treatment,
it is remarkable that depression in MS patients is so in-
frequently treated [3,13]. Apart from general obstacles as
lack of time, no self-perceived need for care or stigma
associated with treatment, MS patients may have
disease-related barriers such as transportation problems,
physical immobility, fatigue and exacerbations of the
disease that might interfere with having face-to-face
treatment [14]. Consequently, medication consults or
face-to-face psychotherapy may not be feasible forms oftreatment for some MS patients [20]. Therefore, alterna-
tive treatment delivery should be considered to increase
access to mental health care. Telephone administered
CBT has previously shown to be more effective in redu-
cing depressive symptoms in MS patients compared to
MS patients receiving supportive emotion-focused ther-
apy [21] or no mental healthcare at all [22]. Recently,
the Internet has grown as an important tool for deliver-
ing mental health interventions [23]; Internet-based
CBT or PST appear to be as effective as face-to-face
therapy [24] and a successful method of treatment for
depression in general [24,25]. Internet-based treatment
is easily accessible, cost-effective and can reach a large
number of people with functional impairments due to
physical health problems which makes it an attractive
treatment for the MS population.
However, there are few publications on Internet-based
treatment for depressed MS patients. Recently, a multi-
center trial was suggested, based on a pilot study that
explored Internet-based CBT for the treatment of de-
pression [26]. Qualitative data from this research group
showed that existing Internet-based CBT packages might
not just be appropriate for MS patients due to MS
related physical and cognitive impairments, inappropri-
ate content, social isolation and problems with computer
use [27]. However, data from our recent pilot study on
Internet-based treatment for depression in MS showed
evidence that Internet-based self-help PST treatment
[28], adjusted to MS patients, can be a feasible treatment
[29]. Patients reported satisfaction with the intervention
which reduced depressive symptoms, especially in those
MS patients who completed the intervention. These
findings encourage us to examine the effectiveness of
this Internet-based self-help course for treatment of de-
pressive symptoms in MS in a randomized controlled
trial (RCT) with longer follow-up. With an easily access-
ible Internet-based self-help intervention we hope to im-
prove the level of care and treat a group of MS patients
with depressive symptoms who could experience
disease-related barriers to participate in face-to-face
counselling.
Unfortunately, dropout percentages from Internet-
based interventions can be high and do not get enough
attention [30]. Also in our pilot study, almost half of the
patients did not complete the intervention. Ways to in-
crease compliance rates should therefore be considered.
However, specific components that are critical in im-
proving compliance are difficult to identify and experi-
mental manipulation of factors likely to increase
compliance in e-health trials are scarce [31]. A meta-
analysis suggests that use of mobile phones and text-
messaging could improve healthcare outcomes and the
processes of care [32] and a RCT showed that telephone
reminders increased the frequency of visits to the site of
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compared to no reminders [33]. Recently, Mohr and
colleges [34] investigated the feasibility of a multimodal
e-mental health treatment for depressed patients in a
pilot study, and suggested that joint effects of Internet
and telephone administered support for depression are
promising. In order to further increase compliance, we
therefore plan to use telephone support in the form of
text-messages in addition to the Internet-based interven-
tion. However, whether extra text-messages would en-
hance compliance rates for Internet-based PST is not
known.
The aims of our RCT will therefore be multiple. First,
we will examine the effectiveness of an Internet-based
PST self-help intervention on the primary outcome
measure depressive symptoms in MS patients and on
secondary outcome measures related to depression and
MS such as quality of life, fatigue and cognitive func-
tioning. If the intervention shows to be effective, predic-
tors of a favorable outcome will be further explored.
Finally, we will investigate whether text-messages added
to the intervention will be effective to increase compli-
ance rate of Internet-based treatment.
Methods
Study design
The presented study is a RCT in which a 5-week Inter-
net-based self-help PST intervention will be tested ver-
sus a waiting list control group. Eligible and consenting
patients will be assessed at baseline (T0), within a week
after the intervention (T1), at four months (T2) and at
ten months follow-up (T3: only the intervention group).
The control group will be measured at the same
moments in time. Patients in the waiting list condition
who still want to participate in the intervention after
they completed the four months follow-up assessment
are again measured after the intervention (T4), four
months later (T5) and at ten months follow-up (T6).
Data will be collected by self-report measures adminis-
tered through the Internet. In addition, a telephone
interview at baseline will be carried out by trained re-
search staff.
Randomization takes place at individual level after
baseline measurements (T0). We will use block-
randomization with variable block sizes. A randomly
allocated number of patients who take part in the inter-
vention will receive supportive text-messages on their
mobile phones in addition to the intervention. Alloca-
tion will be unknown to the investigators and will be
performed by an independent researcher using a compu-
terized random digit generator. The study protocol was
approved by the Medical Ethics Committee of the VU
University Medical Center (VUmc) (registration number
11/047). Written informed consent is obtained from allparticipants. Figure 1 displays the flowchart of the study
design.
Recruitment
MS patients will be recruited from the Neurology De-
partment of the VUmc, through calls in MS newsletters
and Internet-sites concerning MS (e.g. Dutch MS co-
operation; MS Centres), at MS meetings and via MS
nurses. Interested patients will be asked to complete an
online screening on their depressive symptoms, and sev-
eral socio-demographic and MS-specific questions (i.e.
year of diagnosis, onset of first symptoms, medication
usage, type of MS). Eligible patients will be further
informed about the study and asked to return written
informed consent. Subsequently, patients general practi-
tioner (GP) and neurologist will be informed about
participation.
Inclusion and exclusion criteria
MS patients with depressive symptoms who are willing
to take part in an Internet-based self-help course can
participate in the study. Patients (i) have to be 18 years
or older, (ii) score 20 or higher on the Beck Depression
Inventory (BDI-II) [35], indicating a moderate or severe
depression and (iii) report a diagnosis of definite MS
more than 3 months ago which will also be confirmed
by their neurologist. Potential patients will be excluded
if they are currently receiving psychotherapy, do not
have Internet access, do not have a sufficient command
of the Dutch language, or report suicidal ideation.
Patients will not be excluded if they are taking pre-
scribed medication for depression or anxiety disorders
over 6 weeks with stable dosage.
To exclude patients with suicidal intention, item 9
‘Suicidal thoughts or wishes’ of the BDI-II will be used.
Patients who score ‘3’ (“I would kill myself if I had the
chance”), will be contacted, further assessed and
excluded and referred to their GP if necessary. Suicidal
ideation will be also checked with an interviewer-rated
scale of current suicidal ideation of the WHO-
Composite International Diagnostic Interview (CIDI,
World Health Organiszation (WHO) version 2.1) [36].
Patients with a score of 29 or higher on the BDI-II will
be monitored extra.
Interview
A clinical diagnosis of Major Depression Disorder and/
or Anxiety Disorder according to DSM-IV-TR criteria
will be established by a standard telephonic interview
using the WHO CIDI [36]. Neurological and medical
conditions can create difficulties in assessing depression
by a structured measurement as the CIDI. The CIDI
asks patients how much of their sadness and anhedonia
is a result of their medical illness or medications. In case
Figure 1 Flowchart of the study design.
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to these attributes, a psychiatric diagnosis is not given.
We decided that in case MS patients reported their MS
or MS medication to be the reason for their sadness or
anhedonia, the interviewer makes a note and scores the
item negatively.
Further, the Perceived Need of Care Questionnaire
(PNCQ) [37] will be used to measure patients' utilization
of health care resources, needs for mental health care and
the meeting of those needs. Further, the telephonic version
of the Expanded Disability Status Scale [38] will be used to
asses physical (MS) functioning and disability level.
Outcome measures
Primary outcome measure
The primary outcome is the change in depressive symp-
toms defined by a change in the sum score on the BeckDepression Inventory (BDI-II, second edition) [35,39].
This self-report instrument is most often used to meas-
ure depression severity in MS patients [3], and has
shown to be valid, reliable and appropriate for the MS
population [40,41].
Secondary outcome measures
Secondary outcomes will include measures of anxiety,
fatigue, cognitive functioning, physical and psychological
impact of MS, quality of life, problem solving skills, so-
cial support, mastery, satisfaction and compliance rate.
The measurement scales mentioned below have shown
to be reliable, valid and responsive, and are widely used
as an outcome measure in MS research and/or research
on psychiatric conditions.
Anxiety will be assessed with the Beck Anxiety Inven-
tory [42] and the subscale of the Hospital Anxiety and
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Scale (FSS) [44] and Multiple Sclerosis Neuropsycho-
logical Questionnaire (MSNQ) [45] to measure fatigue
and cognitive functioning, respectively. In addition, we
will use the Multiple Sclerosis Impact Scale (MSIS-29)
[46] to assess the physical and psychological impact of
MS and the EuroQol quality of life measure comprising
a five-part questionnaire (EQ-5D) and a visual analogue
self-rating scale (EQ-VAS) [47]. Social support will be
measured with the Social Support Inventory [48] which
contains questions on details about social support from
the four most intimate persons. We will use the Social
Problem Solving Inventory-Revised (SPSI-R) to deter-
mine individual problem-solving skills [49]. Further-
more, Mastery or locus of control, is measured by an
abbreviated version of the Pearlin Mastery Scale [50].
Between follow-ups; psychotherapy and -medication
usage will be registered.
With the Client Satisfaction Questionnaire (CSQ-8)
[51] we will check whether patients were satisfied with
the care they received. The Visual Analogue Scale (VAS)
will be assessed to evaluate patients opinions about the
intervention as a whole, the website and received sup-
port, (via the website and by text-messages if applicable)
and additionally explore reasons for drop-out. Feasibility
of additional text-messages will further be assessed by
compliance rate; data on number of treatment sessions
and drop-out will be collected. Table 1 describes the
measures used at each assessment point.Table 1 Summary of measures
Measure T0: Basel
Interview:
Composite International Diagnostic Interview (CIDI) X
Perceived Need of Care Questionnaire (PNCQ) X
Expanded Disability Status Scale (EDSS) X
Self-report measurements:
Demografics & Medical MS data X
Medication and treatment information X
Beck Depression Inventory (BDI-II) X
Beck Anxiety Inventory (BAI) X
Hospital Anxiety and Depression Scale (HADS-A) X
Fatigue Severity Scale (FSS) X
Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) X
Multiple Sclerosis Impact Scale (MSIS-29) X
EuroQol (EQ-6D) X
Social Support Inventory X
Social Problem Solving Inventroy-Revised (SPSI-R) X
Pearlin Mastery Scale X
Client Staisfaction Questionnaire (CSQ-8)
Visual Analoge Scale (VAS) to evaluate the interventionInternet-based problem solving treatment
The Internet-based self-help intervention examined in
this study is an online problem solving therapy (PST)
[16]. We adjusted the original online intervention [28]
for MS patients with co-morbid depression, conserving
the intent of the PST-based intervention. Modifications
concerned additional information about MS and its psy-
chosocial consequences and texts and examples applying
to MS patients. We also added a mood-chart to the
intervention for daily mood-registration during the
course. The mood-chart could stimulate patients to visit
the website regularly and therefore enhance compliance.
In addition, it offers the possibility to monitor the
patients mood. The whole intervention exists of five
modules with text, exercises and figures, and is called
‘Worry Less’ (“Minder Zorgen”). Patients are asked to at-
tend one module a week and work on their assignments
for at least 2 hours per week.
Patients can access the intervention from their personal
computers via the Internet (https://minderzorgen.e-behan-
deling.nl). Support during the intervention will be pro-
vided by trained psychologists and supervised clinical
psychology Master students, and consists of communica-
tion through brief, weekly e-mails sent through the web-
site and a weekly standardized e-mail to announce a new
module. The e-mail correspondence is merely intended to
facilitate the patient’s effective use of the self-help method.
Patients have the possibility to contact their coach at any
moment for additional support via the website.ine T1: posttreatment T2: 4-months
Follow-up
T3: 10-months
Follow-up
X X X
X X X
X X X
X X X
X X X
X X X
X X X
X X X
X X X
X X X
X X X
X X
X
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As part of the intervention, a number of patients will re-
ceive weekly text-messages on their mobile phones to
support them during the intervention with the aim to
enhance compliance. Patients will be randomly assigned
to the intervention with- or without text-messages. In
the latest case, patients will receive four standard text-
messages a week. Text-messages will be sent to their
mobile phones 1) at the start of a new module, 2) during
the week to remind patients to fill in the exercise and
mood-chart, 3) when homework is handed in by email,
and 4) when feedback is returned by their coach. When
homework is not handed in on time, patients will receive
a reminder text-message. Patients cannot reply to the
text-messages.
Waiting list control group
Patients randomized to the waiting list control group re-
ceive no Internet-based PST. In accordance with the
procedure of patients who participate in the interven-
tion, patients in the waiting list control group are free to
accept any medical or psychological intervention given
in the time period of the study. The received mental
healthcare will be registered. After completion of the
four months follow-up assessment, patients are offered
to participate in the Internet-based intervention on vol-
untary basis irrespective their BDI-II score at T2.
Patients who subsequently take part in the intervention
and follow-up measurements will be additionally
analysed.
Sample size
The power calculation is based at the comparison at T1
to T0 between the two groups. We want to be able to
demonstrate moderate effects (d= 0.5) on the primary
outcome measure, while using a power 0.80, with alpha
set at .05 (two-tailed). Therefore, a total set of N= 64
completers is needed in each condition. Taking into ac-
count the drop-out percentage of our pilot, we aim to
include 166 patients.
Analysis
Non-parametric and parametric statistical tests are used
to assess differences between the conditions with regard
to baseline assessment of all relevant demographic and
clinical variables. Missing data will be processed using
regression imputation or a conservative Last Observa-
tion Carried Forward method (LOCF) (depending on the
sort and size of the missing data). Analysis will be based
on the intention-to-treat principle. Paired t-tests are
used to assess the changes within each condition be-
tween pre-treatment and post-treatment. Difference in
outcome between the Internet-based intervention and
waiting list control group is evaluated by means ofmixed model analysis of covariance and baseline differ-
ences will be included as a covariate in the analyses.
Treatment effect over time will be tested by adding a
group*time interaction term into the model. Cohen’s for-
mula will be used to evaluate the magnitude of the effect
of the intervention on outcome measures [52]. To calcu-
late clinically significant improvement and recovery we
will use the standardized method of Jacobson and Truax
[53]. If the intervention shows to be effective, predictors
of outcome will be explored by analyses of interaction
between patients characteristics and treatment. Data of
waiting list patients who decided to participate in the
intervention will be analysed separately. Finally, descrip-
tive statistics of compliance rate and satisfaction will be
used to explore the feasibility of text-messages as a way
to increase compliance rate to Internet-based treatment.Discussion
The described study protocol is designed to investigate
the effectiveness of an Internet-based self-help PST
intervention for depressive symptoms in MS patients in
a RCT. Treatment through Internet offers the possibility
to reach a group of underserved MS patients who could
experience disease-related barriers to participate in face-
to-face counselling. Besides, the self-help aspect of
Internet-based treatment could be appealing to a group
of patients that already is dependent of professionals in
the medical circuit because of their MS. According to
our knowledge, the effectiveness of Internet-based treat-
ment for depressive symptoms in MS patients has not
been examined yet. Our trial will also shed more light
on the applicability of PST in itself for patients who suf-
fer from MS.
In order to conduct a high-quality trial, a multidiscip-
linary team with various expertises related to MS and
depression was involved in the development of the inter-
vention and the study design. Ways to prevent early ter-
mination during the intervention were carefully taken
into account since high drop-out percentages in e-health
interventions are a common phenomenon. Although
multimodal e-mental health treatment seems a promis-
ing candidate to increase compliance, additional research
on this subject is needed [34]. Evaluation of the effect-
iveness of text-messages in addition to Internet-based
treatment seems therefore a valuable aspect of our trial.
Nevertheless, it is still unclear whether effectiveness of
additional text-messages can be determined as the trial
is powered to demonstrate effects of the intervention
and not of text-messaging. Further, follow-up assess-
ments to explore Internet-based PST effects on the
long-term could be considered another strength of our
trial since data on enduring treatment effects for depres-
sion in MS are often not available [11].
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the low level of exclusion criteria and the use of Internet
that enables us to reach and treat a large part of the MS
population. It should be noted that Internet-based treat-
ment may not be suitable for MS patients who are not
familiar with the Internet, or who suffer from MS related
problems such as impaired vision and arm/hand dys-
function. In addition, we will exclude patients with mild
depressive complaints (BDI-II < 20). As a consequence,
evidence will be lacking whether the intervention could
be effective for this group of patients. However, our
pilot-study [29] showed that patient with more severe
depressive symptoms experienced more benefit from the
intervention than patients with fewer depressive com-
plaints. Moreover, patients with fewer depressive symp-
toms at baseline (<20) were more likely to drop out of
treatment and indicated to be less satisfied with the
intervention. A meta-analysis [23] supports this finding
and suggests that patients with less severe psychological
difficulties may be less motivated to receive ongoing
help. Driessen and colleagues concluded in their meta-
analysis [54] that psychological treatment might even be
more efficacious for more severely depressed patients
than low severely depressed patients. For these reasons
we decided to focus on MS patients with moderate or
high depressive complaints.
To conclude, a study protocol to investigate the effect-
iveness of Internet-based PST for depressive symptoms
in MS patients is presented in order to enhance meth-
odological clarity and further research on treatment for
depressed MS patients. Internet-based PST offers the
possibility to reach and treat many MS patients with de-
pressive symptoms and to improve the quality of care.
Our RCT is aimed at contributing to better recognition
and adequate treatment of depressive symptoms in MS
patients in the future.
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